Aardvark Therapeutics, Inc. (AARD) · Oct 8, 2026 · Exec change
Board appointment — 25+ years in clinical strategy, biostatistics and regulatory submissions
Aardvark’s new board appointment brings Phase 3 and regulatory expertise, but does not resolve the FDA hold blocking ARD-101’s path forward.
Aardvark is a clinical-stage biotech whose lead asset, ARD-101, is intended to treat hyperphagia in Prader-Willi Syndrome, but the program remains constrained by an FDA clinical hold while the company works out its next development path.
The appointment adds relevant expertise at the exact bottleneck. David Zhang brings more than 25 years across pivotal-trial design, biostatistics and regulatory submissions, including work on the Phase 3 program and NDA for CAMZYOS; the filing says he was appointed as an independent Class II director effective October 7, 2026. 〔0〕
This is capability added, not a program breakthrough. Zhang’s stated remit is to help navigate the regulatory landscape and shape ARD-101’s next phase, but the filing provides no FDA decision, clinical-hold resolution, trial restart, new data or development timeline. His own description that Aardvark is at a “pivotal moment” reinforces that the core uncertainty remains unresolved. 〔1〕
The economics are standard board compensation rather than a major financing signal. He receives $40,000 annually in cash, prorated, plus a $500,000 stock-option award vesting monthly over 36 months, with full vesting upon a change in control. That creates ordinary dilution and retention incentives, but does not materially change the company’s funding or operating position.
Bottom line: This modestly strengthens Aardvark’s regulatory and clinical-development bench, but it does not advance ARD-101 past its central FDA hurdle. The business story is still waiting on the agency and the company’s path-forward decision, so the appointment matters more as preparation than as a change in operating status.
FDA discussions and ARD-101 path-forward update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!